CN111184133A - Pet health product and preparation method thereof - Google Patents
Pet health product and preparation method thereof Download PDFInfo
- Publication number
- CN111184133A CN111184133A CN202010133729.1A CN202010133729A CN111184133A CN 111184133 A CN111184133 A CN 111184133A CN 202010133729 A CN202010133729 A CN 202010133729A CN 111184133 A CN111184133 A CN 111184133A
- Authority
- CN
- China
- Prior art keywords
- leu
- biological enzyme
- ala
- gly
- val
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/153—Nucleic acids; Hydrolysis products or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Food Science & Technology (AREA)
- Birds (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The application provides a pet health product which comprises β -1, 0.01-50% of 3-glucan and 0.01-50% of nicotinamide mononucleotide in percentage by weight, and the pet health product is beneficial to improving intestinal tracts, improving cell activity, promoting metabolism and delaying senescence.
Description
Technical Field
The application relates to the technical field of pet foods, in particular to a pet health product and a preparation method thereof.
Background
With the increase of economy, the pet industry has been rapidly developed, and the pet food on the market is also good and uneven. Because of the quality of the pet food, the nutrition intake of the pet is determined and is related to the health of the pet; good diet is essential to ensure the health of pets, and the choice of food items for good pets is very critical to them. Research shows that pets with aging and low immunity are easy to be infected with diseases, and in order to improve the immunity of pets, special pet food is required to be fed to the pets except for paying attention to sanitary feeding habits. At present, the traditional pet formula food or formula food lacks products with real efficacy, and most of the traditional antioxidant raw materials such as vitamin E and the like are taken as main materials; or the raw materials surrounding the addition of various trace elements. Therefore, the development of the pet health care product which is beneficial to delaying senility and enhancing immunity is of great significance.
Disclosure of Invention
In order to solve the above technical problems, the present application provides a pet health product having effects of improving intestinal tracts, increasing cell activity, promoting metabolism, and delaying aging, and a method for preparing the same.
In a first aspect, the present application provides a pet health product comprising β -1, 3-glucan 0.01-50% and Nicotinamide Mononucleotide (NMN) 0.01-50% by weight.
Optionally, the mass ratio of β -1,3 glucan to nicotinamide mononucleotide is 1 (1-100).
Optionally, the mass ratio of β -1,3 glucan to nicotinamide mononucleotide is 1 (1-50), further optionally, the mass ratio of β -1,3 glucan to nicotinamide mononucleotide is 1 (2-10), for example, the mass ratio of β -1,3 glucan to nicotinamide mononucleotide is specifically 1 (1-5), 1 (1-10), 1 (2-30), 1 (1-40), 1 (1-50), 1 (1-60), 1 (1-70), 1 (1-80), 1 (1-90) or 1 (1-100).
According to the pet health product composition, intestinal health can be effectively maintained, β -1,3 glucan and nicotinamide mononucleotide in the pet health product play a synergistic effect, β -1,3 glucan can obviously improve an antioxidant index, so that immunity of a pet is improved, aging is delayed, nicotinamide mononucleotide provides an energy source ATP for cells, metabolism and cell renewal are enhanced, absorption and function implementation of glucan are facilitated, the nicotinamide mononucleotide also has an aging delaying function, the function is improved after being matched with glucan, and the whole pet health product can show a more prominent anti-aging effect.
Specifically, β -1,3 glucan can induce the proliferation, secretion and phagocytic activity of macrophages, wherein the induced IL-1 (interleukin-1) can indirectly stimulate Th cells (helper T cells) to secrete anticancer cytokines such as IL-2 (interleukin-2), and the like, the induction of the cytokines can start a series of biological reactions, such as IL-1 promoting the proliferation and activation of cells such as T, B, NK and the like, IL-2 inducing LAK (killer cell activated by lymphokine) and TIL (tumor infiltrating lymphocyte) and the like to kill pathogenic microorganisms, β -1, 3-glucan has an obvious bidirectional characteristic on the regulation of immune response, namely shows positive regulation (immune enhancement) under the condition of adaptive dosage, but shows negative regulation (immune inhibition) under the condition of excessive dosage.
In the present application, nicotinamide mononucleotide is NAD+(nicotinamide adenine dinucleotide) synthesized precursor, after entering cells, synthesizes NAD through a one-step metabolic process+It can improve the vitality and immunity of cells by promoting the cells to produce Adenosine Triphosphate (ATP).
Optionally, the nicotinamide mononucleotide is more than 99% pure the β -1,3 glucan is more than 70% pure, for example, the β -1,3 glucan is 70% -95% pure.
Optionally, further active components are included, the further active components including at least one of vitamins, antioxidants and minerals.
Optionally, the vitamins include one or more of vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin D, and vitamin E; the antioxidant comprises one or more of Butylated Hydroxyanisole (BHA), dibutyl hydroxy toluene (BHT), Propyl Gallate (PG), D-sodium erythorbate and tea polyphenol; the mineral comprises mineral elements including one or more of magnesium, iron, zinc, copper, calcium, iodine and manganese.
Optionally, in the mineral, magnesium can be derived from one or more of magnesium sulfate, magnesium chloride and magnesium citrate; the iron can be one or more of ferrous gluconate, ferrous sulfate, ferrous lactate, ferric citrate and ferric pyrophosphate; the zinc can be one or more of zinc sulfate, zinc gluconate, zinc lactate and zinc chloride; the copper may be derived from copper sulfate; the calcium can be selected from one or more of milk calcium, calcium citrate, calcium phosphate, calcium chloride, calcium carbonate and calcium lactate; iodine may be derived from potassium iodide; the manganese may be derived from manganese sulfate.
Optionally, the pet care product further comprises one or more of a filler, an excipient, and a preservative. Optionally, the bulking agent comprises one or both of a plant starch and a dextrin; the excipient comprises one or more of calcium carbonate, sucrose powder, lactose powder and pectin; the preservative comprises one or more of potassium sorbate, sodium benzoate, calcium propionate, and sodium propionate.
Optionally, in the daily dosage of the pet health product, the β -1, 3-glucan is 1-1000 micrograms/kg of body weight, and the nicotinamide mononucleotide is 1-2000 micrograms/kg of body weight.
The pet health product can be in the form of capsules and can also be in the form of pet feed.
In a second aspect, the present application also provides a method for preparing a pet health product according to the first aspect of the present application, comprising:
weighing the components according to the formula proportion, putting the components into a stirring pot, and stirring to obtain a mixed material; and then, after forming and drying, cooling to room temperature, and then accommodating in a packaging container and sealing to obtain the pet health product.
Optionally, after the mixture is obtained after the stirring, before the molding, the grinding of the mixture is further performed. Wherein, the particle size of the mixed material after grinding treatment can be adjusted based on practical application. In one embodiment, the particle size of the mixture after the grinding process is 100-.
Alternatively, the packaging container may be a capsule, and the packaging container may also be other forms of packaging. For example, the pet care product described herein is shown in fig. 1.
Optionally, the β -1,3 glucan is prepared by a fermentation process, and the specific fermentation process comprises:
preparing culture solution, inoculating zymocyte into the culture solution, fermenting at 28-32 deg.C until OD600 value of the culture solution is greater than 0.6-0.9, separating and extracting β -1,3 dextran, wherein the culture solution contains potassium dihydrogen phosphate (KH)2PO4) Sodium nitrate (NaNO)3) Magnesium sulfate (MgSO)4) Calcium chloride (CaCl)2) Ferrous chloride (FeCl)2) Sucrose and agar.
Optionally, the mass fractions of the components in the culture solution are: KH (Perkin Elmer)2PO41‰,NaNO33‰,MgSO40.2‰,CaCl20.07‰,FeCl20.0125 per mill, 20 per mill of cane sugar and 0.9 percent of agar. The "% o" here is a thousandth, representing a few thousandths of a word.
Optionally, the pH of the culture broth is 7.0-7.2. The activity of the zymophyte in the pH range is more prominent, and the fermentation efficiency and the fermentation quality are improved.
Alternatively, the fermenting bacteria may be, but not limited to, Agrobacterium ZX09(Agrobacterium sp. zx09).
Continuously, in the fermentation process, the culture solution inoculated with the zymophyte is continuously stirred, and air is introduced, wherein the stirring speed is 100-300rpm, and the ventilation volume is 0.3-0.5 vvm.
Optionally, the fermentation time can be adjusted based on the OD600 value of the culture solution during the fermentation process. In one embodiment, the fermentation time is 16-30 hours.
Further, optionally, during the fermentation process, the fermentation temperature may be specifically 30 ℃.
According to the application, β -1,3 glucan with the purity of more than 70% can be obtained after β -1,3 glucan prepared by fermentation is separated and extracted, since β - (1,3) glucan is usually extracted from shiitake mushroom, lucid ganoderma, yeast or microalgae in the prior art, a large amount of raw materials are consumed, the yield is very low, the purity is low, and the production cost is very high, secondly, a large amount of acid, alkali and organic solvent are applied in the extraction process, so that a large amount of waste water is unfavorable to the environment, meanwhile, β - (1,3) glucan from yeast and microalgae is not water-soluble, the biological activity is low, compared with the prior β -1,3 glucan preparation process, β - (1,3) glucan prepared by the method has the characteristics of high yield and high purity, and the raw material cost of β - (1,3) glucan can be greatly reduced.
Optionally, the method for synthesizing nicotinamide mononucleotide comprises:
constructing a biological enzyme recombinant plasmid, and performing protein expression and purification to obtain biological enzymes, wherein the biological enzymes comprise a first biological enzyme, a second biological enzyme, a third biological enzyme and a fourth biological enzyme; the first biological enzyme comprises the amino acid sequence as set forth in SEQ ID NO:1 and the second biological enzyme comprises the nucleotide sequence shown as SEQ ID NO: 2 and the third biological enzyme comprises the nucleotide sequence shown as SEQ ID NO: 3 and the fourth biological enzyme comprises the nucleotide sequence shown as SEQ ID NO: 4;
preparing a reaction solution, wherein the reaction solution contains inosine, adenosine diphosphate and adenosine triphosphate, adding the first biological enzyme, the second biological enzyme and the third biological enzyme into the reaction solution, generating 5-phosphoribosyl pyrophosphate after biocatalysis, adding nicotinamide and the fourth biological enzyme, and separating to obtain nicotinamide mononucleotide after biocatalysis.
Alternatively, the vector plasmid used for the recombinant plasmid of the biological enzyme is pET22b (+). The specific process of preparing the biological enzyme can be as follows: after the biological enzyme recombinant plasmid is transfected into the microbial strain, inducing the microbial strain containing the biological enzyme recombinant plasmid in a microbial culture solution to express the biological enzyme. The microbial strains comprise one or two of Rosetta (DE3) Escherichia coli and BL21(DE3) Escherichia coli. Further optionally, the microbial strain comprises Rosetta (DE3) escherichia coli.
The biological enzyme may be produced intracellularly by the microorganism strain, or may be produced intracellularly by the microorganism strain and then released into the culture medium of the microorganism. And collecting the microbial strains capable of expressing the biological enzyme, cleaning, breaking cells and collecting to obtain the crude enzyme solution, wherein the crude enzyme solution contains the biological enzyme. Then obtaining the biological enzyme after the subsequent protein purification process. In one embodiment, the purified biological enzyme protein may be obtained by nickel column purification.
Optionally, the first biological enzyme comprises a sequence as set forth in SEQ ID NO: 5. The second biological enzyme comprises the amino acid sequence shown as SEQ ID NO: 6. The third biological enzyme comprises the amino acid sequence as shown in SEQ ID NO: 7. The first biological enzyme comprises the amino acid sequence as set forth in SEQ ID NO: 8.
Alternatively, the genes encoding the biological enzymes including the first biological enzyme, the second biological enzyme, the third biological enzyme and the fourth biological enzyme should take into account degenerate bases. Taking the first biological enzyme as an example, the coding gene of the amino acid sequence shown in SEQ ID NO. 5 comprises the nucleotide sequence shown in SEQ ID NO. 1, and the protection scope should also protect the nucleotide sequence with base degeneracy with the SEQ ID NO. 1, and the corresponding amino acid sequence of the nucleotide sequence is still SEQ ID NO. 5.
The gene encoding the biological enzyme may be inserted into a multiple cloning site of a vector plasmid, for example, between the sites of BamHI, EcoRI or Xho I. When the coding gene of the biological enzyme is inserted into a pET22b (+) vector plasmid, an initiation codon (such as ATG) can be added at the 5' end of the coding gene of the biological enzyme; a stop codon (e.g., TAA) may be added to the 3' end. In one embodiment, the gene encoding the biological enzyme may be inserted between the cleavage sites of "CATATG" and "CTCGAG" of the vector plasmid.
Optionally, the reaction liquid further comprises sodium carbonate, magnesium chloride and potassium chloride. Sodium carbonate, magnesium chloride and potassium chloride in the reaction solution can be used for assisting enzyme catalysis reaction, and the activity of the biological enzyme is improved.
The nicotinamide mononucleotide synthesized by using the biological enzyme catalysis is high in yield and purity; the cost can be greatly saved; the purity of the prepared nicotinamide mononucleotide can reach more than 99%.
The beneficial effects of the application comprise the following aspects:
1. the pet health product can effectively maintain intestinal health, β -1,3 glucan and nicotinamide mononucleotide in the pet health product play a synergistic effect, β -1,3 glucan can obviously improve the level of short-chain fatty acid in cecum and improve the health level of intestinal tract, so that immunity of pets delays aging, nicotinamide mononucleotide provides energy source ATP for cells, metabolism and cell renewal are enhanced, absorption and function implementation of glucan are facilitated, nicotinamide mononucleotide has the function of delaying aging, the function is improved after being matched with glucan, and the whole pet health product can show more prominent anti-aging effect.
2. The preparation method of the pet health product is simple in process, environment-friendly and widely suitable for industrial mass production, and the β -1, 3-glucan and nicotinamide mononucleotide in the raw materials is low in preparation cost and high in purity, so that the production cost of the pet health product can be further reduced, and the anti-aging effect of the pet health product is improved.
Advantages of the present application will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the embodiments of the present application.
Drawings
In order to more clearly explain the content of the present application, the following detailed description is given in conjunction with the accompanying drawings and specific embodiments.
FIG. 1 is a schematic view of a pet health product provided in an embodiment of the present application;
FIG. 2 is a SDS-PAGE pattern of a first biological enzyme according to an embodiment of the present application;
FIG. 3 is an SDS-PAGE pattern of a second biological enzyme according to an embodiment of the present application;
FIG. 4 is an SDS-PAGE pattern of a third biological enzyme according to an embodiment of the present application;
FIG. 5 is an SDS-PAGE pattern of a fourth biological enzyme according to an embodiment of the present application;
FIG. 6 is a diagram of a specific bio-enzyme catalytic process pathway of nicotinamide mononucleotide, provided in an embodiment of the present application.
Detailed Description
While the following is a preferred embodiment of the embodiments of the present application, it should be noted that those skilled in the art can make various improvements and modifications without departing from the principle of the embodiments of the present application, and such improvements and modifications are also considered to be within the scope of the embodiments of the present application.
Unless otherwise specified, the raw materials and other chemical agents used in the examples of the present application are commercially available.
(1) β preparation of 1, 3-glucan
The β -1, 3-glucan is prepared by fermentation method, and the method comprises preparing culture solution, inoculating zymocyte ZX09 into the culture solution, wherein the culture solution is KH2PO41‰,NaNO33‰,MgSO40.2‰,CaCl20.07‰,FeCl20.0125 per mill, 20 per mill of cane sugar and 0.9 percent of agar, wherein the pH value of the culture solution is 7.0-7.2, the culture solution is fermented in a fermentation tank at the temperature of 30 ℃, the stirring speed is 200rpm, the ventilation quantity is 0.4vvm, the fermentation is carried out for 1 day until the OD600 value of the culture solution is more than 0.9, and β -1,3 glucan obtained by separation and extraction is obtained, wherein the purity of the extracted β -1,3 glucan is more than 70%.
(2) Preparation of nicotinamide mononucleotide
(a) Construction of pET22b (+) -NMN recombinant plasmid
The gene sequence of the biological enzyme is synthesized by the whole gene, the biological enzyme comprises a first biological enzyme, a second biological enzyme, a third biological enzyme and a fourth biological enzyme, and the gene sequences are respectively shown as SEQ ID NO: 1-SEQ ID NO: 4, respectively and correspondingly constructing a plasmid pET22b (+), wherein a biological enzyme gene of the nucleotide sequence is inserted between Nde I and Xho I enzyme cutting sites in the vector plasmid; when the biological enzyme gene is inserted into a vector plasmid, a stop codon (such as TAA) can be added at the 3' end of the coding sequence of the biological enzyme gene to be connected with an XhoI enzyme cutting site in the vector plasmid.
(b) Expression of biological enzymes
Escherichia coli containing the recombinant plasmid pET22b (+) -NMN was inoculated at 1% inoculum size into a 50mL Erlenmeyer flask containing 10mL LB medium (100. mu.g/mL ampicillin (Amp)), maintained at 37 ℃ with a constant shaking rate of 200rpm, overnight culture was performed, then the inoculum size of 1% inoculum size was transferred to a 2L Erlenmeyer flask containing 1L LB medium (100. mu.g/mL Amp), incubation was continued at 37 ℃ until the OD600 value in the medium reached about 0.6, isopropyl- β -D-thiogalactoside (IPTG) inducer (final concentration of 0.5mM) was added, the cells were cultured at 37 ℃ for 8 hours, centrifuged and collected, then resuspended in 4-fold mass of 100mM potassium phosphate buffer (pH 6.5) and sonicated for 20min to obtain a crude NMN-synthesizing bio-enzyme solution.
And (3) carrying out protein purification on the NMN biological enzyme crude enzyme solution obtained by expression. Purifying the obtained various biological enzymes by a nickel column separation and purification method, and eluting by using imidazole with different concentrations; and then identified by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), see FIGS. 2-5. Wherein the molecular weights of the first biological enzyme, the second biological enzyme, the third biological enzyme and the fourth biological enzyme are respectively about 32KDa, 21KDa and 58 KDa. The biological enzyme protein obtained by nickel column purification is preserved for standby.
(c) Catalytic synthesis of nicotinamide mononucleotide
Preparing reaction liquid, taking inosine, adenosine diphosphate, adenosine triphosphate and nicotinamide as raw materials, taking sodium carbonate, magnesium chloride and potassium chloride as auxiliary materials, and preparing the nicotinamide mononucleotide under the catalysis of biological enzymes, wherein the synthesis route is shown in figure 6, inosine in the reaction liquid generates 1-phosphoribosyl under the catalysis of first biological enzymes, and then 1-phosphoribosyl, adenosine diphosphate and adenosine triphosphate generate 5-phosphoribosyl pyrophosphate under the catalysis of second biological enzymes and third biological enzymes. The obtained 5-phosphoribosyl pyrophosphate and the added nicotinamide generate nicotinamide mononucleotide under the catalysis of fourth biological enzyme, and then the nicotinamide mononucleotide is obtained by separation and extraction. The purity of the nicotinamide mononucleotide can reach more than 99%.
Example 1
A preparation method of a pet health product comprises the following steps:
β -1, 3-glucan 5mg, nicotinamide mononucleotide 10mg and vitamin C3 mg prepared by the preparation method are uniformly mixed and then filled into capsules to obtain the pet health care product.
Example 2
A preparation method of a pet health product comprises the following steps:
β -1, 3-glucan 5mg, nicotinamide mononucleotide 10mg and antioxidant D-sodium erythorbate 0.5mg prepared by the preparation method are uniformly mixed and then filled into capsules to obtain the pet health care product.
Example 3
A preparation method of a pet health product comprises the following steps:
β -1, 3-glucan 5mg, nicotinamide mononucleotide 10mg and mineral 0.2mg prepared by the preparation method are uniformly mixed and then filled into capsules to obtain the pet health care product.
Effects of the embodiment
(1) Regulation and control of dog serum antioxidant enzyme activity and alleviation of oxidative damage by pet health product
The material and the method are characterized in that 40 adult dogs (older than 5 years) are selected and randomly divided into 5 treatment groups, 10 treatment groups are selected in each group, the average age and the weight of each group of dogs are close to 30-35 kg.5 treatment groups, (1) a control group 1 is normal dog food, (2) a control group 2 is normal dog food and β -1,3 glucan, (3) a control group 3 is normal dog food and nicotinamide mononucleotide, the health care product is administrated by gastric lavage for 30 days and 60 days, specifically referring to table 1, forelimb vein blood collection and serum centrifugation are carried out, 4) an experimental group 1 is normal dog food and pet health care products, (5) an experimental group 2 is normal dog food and high-content pet health care products, and the serum oxidation resistance index measurement comprises glutathione peroxidase (GSH-Px), superoxide dismutase (SOD) activity and Malondialdehyde (MDA) content.
Wherein, data statistics and analysis: single-factor analysis of variance was performed using SPSS 2.0 statistical software and multiple comparisons were performed using Duncan, with P <0.05 indicating significant differences, and the results are shown in table 2.
TABLE 1 feed rates (mg/kg BW) for various treatment groups for various components of pet health care product
TABLE 2 Effect of Pet health products on canine serum antioxidant enzyme activity and MDA content
Note: the differences (a, b, c) among the same row of shoulder letters indicate significant differences (P < 0.05).
As can be seen from the data in Table 2, the activity of GSH-Px and SOD enzyme in the canine serum of experimental group 1-2 is significantly higher than that of the control group 1-3(P <0.05), and the activity of GSH-Px and SOD enzyme in the canine serum of control group 1 and control group 3 is close, indicating that the activity of nicotinamide mononucleotide on GSH-Px and SOD enzyme is not significant, the activity increasing effect of β -1,3 glucan in control group 2 on GSH-Px and SOD enzyme is limited, significantly lower than that of experimental group 1 and 2(P <0.05), and the trend of results of 30 days and 60 days is the same, meanwhile, the MDA content in the canine serum of experimental group 1-3 is significantly lower than that of experimental group 1 and 2(P <0.05), and the canine serum content of experimental group 1 and 2 is also significantly lower than that of control group 2 and 3(P <0.05), the trend of results of 30 days and 60 days is the same, the canine serum MDA content in experimental group 1 and 2 of this embodiment is significantly lower than that of the antioxidant lipid-increasing effect of nicotinamide mononucleotide in canine serum β, and the antioxidant effect of nicotinamide mononucleotide can be further increased by the synergistic effect of antioxidant lipid-antioxidant effect of the antioxidant lipid-increasing the antioxidant lipid-antioxidant effect of the antioxidant lipid-antioxidant effect of the antioxidant lipid-lipid.
As can be seen from the data in Table 2, compared with the control group 1, the activities of GSH-Px and SOD enzyme in the serum of the dog in the control group 2 are increased to a certain extent, the MDA content is reduced (P <0.05), the activities of GSH-Px, SOD enzyme and MDA content in the serum of the dog in the nucleotide group are not obviously changed, the results of 30 days and 60 days are consistent, which shows that β -1 and 3 glucan fed alone have certain antioxidation, and nicotinamide mononucleotide fed alone has no obvious antioxidation, but the activities of GSH-Px and SOD enzyme in the serum of the dog in the experiment group 1 are obviously higher than those of the control group 2, and the MDA content is obviously lower than that of the control group 2(P <0.05), which shows that β -1,3 glucan and nicotinamide mononucleotide in the pet health care product in the experiment group 1 of the application have synergistic effect, and can greatly improve the antioxidation capability of the dog.
In the experimental group 1 and the experimental group 2 of the embodiment, the pet health product can be fed for more than 30 days to remarkably improve the activity of the antioxidant in the serum of the dog and reduce the content of lipid peroxide in the blood.
The pet health product composition can effectively maintain intestinal health, β -1,3 glucan and nicotinamide mononucleotide in the pet health product play a synergistic effect, β -1,3 glucan can obviously improve an antioxidant index, so that immunity of a pet is improved, and aging is delayed, the nicotinamide mononucleotide provides an energy source ATP for cells, metabolism and cell renewal are enhanced, absorption and function implementation of glucan are further facilitated, the nicotinamide mononucleotide has an aging delaying function, the function is improved after being matched with glucan, and the whole pet health product can show a more prominent anti-aging effect.
The above-mentioned embodiments only express several embodiments of the present application, and the description thereof is more specific and detailed, but not construed as limiting the scope of the present application. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the concept of the present application, which falls within the scope of protection of the present application. Therefore, the protection scope of the present patent shall be subject to the appended claims.
Sequence listing
Qi <110>
Lichenwu tea
Jili Hua
<120> a pet health product and a preparation method thereof
<160>8
<170>SIPOSequenceListing 1.0
<210>1
<211>882
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>1
caccaccatc atcaccacgc gaacggctac acctacgaag actaccaaga tacggccaaa 60
tggctgctga gccataccga acagcgccca caagttgcgg ttatctgtgg cagcggtctg 120
ggtggtctgg ttaataaact gacgcaagcc cagacgttcg actacagcga gatcccgaac 180
tttccggaaa gcaccgttcc gggccatgcc ggtcgcctcg ttttcggcat tctgaacggc 240
cgtgcgtgcg ttatgatgca aggccgcttt cacatgtacg aaggctaccc gttctggaag 300
gttacctttc cggtgcgcgt tttccgtctg ctgggtgtgg aaacgctggt tgttaccaat 360
gcggccggtg gtctgaatcc gaactttgaa gtgggcgaca tcatgctgat ccgcgaccac 420
atcaatctgc cgggtttcag cggcgaaaat ccgctgcgcg gtccgaatga agaacgcttt 480
ggcgtgcgct ttccggccat gagcgatgcg tacgatcgcg atatgcgcca gaaagcgcac 540
agcacgtgga aacagatggg tgaacagcgc gaactgcaag aaggtaccta cgttatgctg 600
ggcggcccga acttcgaaac cgtggccgaa tgccgtctgc tgcgcaatct gggcgcggat 660
gccgtgggta tgagcaccgt tccggaagtg attgttgccc gccattgcgg tctgcgcgtg 720
tttggcttca gtctgatcac caacaaggtg atcatggact acgagagcca aggcaaagcg 780
aaccacgaag aagttctcga agcgggcaaa caagccgccc agaagctgga acagttcgtt 840
agtctgctga tggccagtat tccggtgagc ggccataccg gc 882
<210>2
<211>897
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>2
caccaccacc accatcacaa actggatgtg atcggcatcg gcaatctgaa ctacgacatc 60
atcttcacgc tggaacgctt tccggagttc cacgaaaaga tcaacgcccg cggtgcccat 120
tttggtctcg gtggtgcggc ggccaatacc attagctggc tggcgcactt cggtctgaaa 180
acgggctaca tcggcgccgt gggcaatgat gacgtgggcg agatgcacat caagtacttc 240
caaggcatcg gcgttgatac cggcggcatc gatgttgttg aggaaccgag cggtgttgcg 300
gttgccatgg ttgcgggcga cgataagcgc atcgttaaat acccgggtgc caatctgcgc 360
cgccgcttca aaccggaata cgccagccgc gcgaaatttc tgcatctgag cagcaacccg 420
ccagaactga tcgaagaggc cgtgaacttc gcgagtcaac gcggcatcaa agtgagcctc 480
gatatcggtg aagcgccgct gccacgcgaa ctggaaagca aggtggacta cctcatgatg 540
aacgaggacg agtatcgccg caaatacggt agtctggatc cgagtctgtg ccgcgccaaa 600
aatctggtgg tgacgctgaa tggcggtggt gcgctggttc gcgaaggcga taacgttttc 660
gaggtgcgtg gtctgagcgc caaagtggtt gatagtacgg gcgccggtga tagcttcgat 720
gccggtgtta tctacggcgt tctgaacggt tggagtctgc tggatagcgc caaactgggc 780
atgctgctgg cctatctgac cgttcagaaa gttggtgccc gcagcgccat cgttccgctg 840
gaagaggtta aacgcatcgc ccgcgaggtt ggtctcgatc tcccattcaa tcgcacc 897
<210>3
<211>570
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>3
atgggcaaac tgatctggct gatgggtcca agcggcagcg gcaaagatag tctgctggcg 60
gaactgcgtc tgcgcgaaca aacccagctg ctggttgccc accgctacat cacccgtgat 120
gccagcgccg gcagtgaaaa ccacatcgcg ctgagcgagc aagaattctt cacccgtgcc 180
ggccagaatc tgctggcgct gagctggcac gcgaatggtc tgtactacgg cgtgggcgtt 240
gagattgatc tgtggctgca cgccggcttt gatgttctgg tgaatggcag tcgtgcccat 300
ctgccacaag cccgtgcccg ttatcagagc gcgctgctgc cggtttgtct gcaagttagc 360
ccggaaattc tgcgccagcg tctggaaaat cgcggccgcg aaaatgcgag cgaaatcaat 420
gcgcgtctgg cccgtgccgc gcgttatacc ccacaagatt gccacacgct gaacaacgat 480
ggcagtctgc gccagagcgt ggatacgctg ctgacgctga tccaccagaa agagaaacac 540
cacgcgtgtc tgcatcacca tcatcatcat 570
<210>4
<211>1629
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>4
gccgccgaac aagatccaga agcgcgtgcc gcggcgcgtc cactgctgac cgatctgtac 60
caagcgacca tggcgctggg ttattggcgt gccggtcgtg cgcgtgatgc cgccgaattt 120
gagctgttct ttcgccgttg cccatttggt ggtgcctttg cgctggcggc gggtctccgc 180
gattgcgttc gttttctgcg tgcgttccgt ctgcgcgatg cggatgttca gtttctggcg 240
agtgttctgc caccagatac cgacccggcc ttttttgagc atctgcgcgc gctggattgc 300
agtgaggtta ccgttcgcgc gctgccggaa ggtagtctcg cctttccggg cgtgccgctg 360
ctgcaagtta gcggtccact gctggtggtt cagctcctcg aaacgccact gctgtgtctg 420
gttagctatg cgagtctggt tgcgacgaat gcggcccgtc tgcgtctgat tgcgggtccg 480
gaaaagcgtc tgctggagat gggtctgcgt cgcgcccaag gtccagatgg cggtctcacc 540
gccagtacgt acagctatct gggcggcttt gatagcagta gcaatgttct ggcgggccag 600
ctccgtggtg ttccagttgc gggtacgctg gcccatagct tcgttaccag tttcagcggc 660
agcgaagtgc cgccagaccc aatgctggcc ccggccgcgg gtgaaggccc gggcgttgat 720
ctggcggcca aagcccaagt ttggctggaa caagtttgcg cgcatctcgg tctgggcgtt 780
caagaaccgc atccgggcga acgtgccgcc tttgtggcgt acgcgctggc ctttccacgt 840
gcctttcaag gtctgctgga tacctacagc gtttggcgta gtggtctccc aaatttcctc 900
gcggttgcgc tggcgctggg tgaactcggt taccgcgccg ttggtgttcg cctcgatagc 960
ggtgatctgc tccagcaagc ccaagaaatt cgcaaagtgt ttcgcgccgc ggccgcccag 1020
tttcaagtgc catggctgga aagcgttctg atcgtggtga gtaacaatat cgacgaagaa 1080
gcgctcgcgc gtctggcgca agaaggtagc gaggtgaacg tgatcggcat tggcaccagc 1140
gttgttacgt gcccacagca gccaagtctc ggtggcgtgt ataaactggt tgcggttggt 1200
ggccagccgc gcatgaaact gaccgaggac ccggaaaaac aaacgctgcc gggcagcaaa 1260
gccgcgtttc gtctgctggg cagcgatggt agtccgctca tggatatgct ccagctggcg 1320
gaagaaccag ttccgcaagc gggtcaagaa ctgcgtgttt ggccaccggg cgcgcaagaa 1380
ccatgcacgg ttcgtccagc ccaagttgag ccgctgctcc gtctgtgtct gcaacaaggc 1440
caactgtgcg agccgctgcc gagtctggcg gaaagtcgtg cgctcgcgca gctgagtctg 1500
agccgtctca gcccggaaca tcgccgtctg cgtagtccgg cccagtatca agttgttctc 1560
agtgagcgcc tccaagcgct ggtgaatagt ctgtgtgccg gccagagccc acatcaccac 1620
catcaccat 1629
<210>5
<211>294
<212>PRT
<213> Artificial Sequence (Artificial Sequence)
<400>5
His His His His His His Ala Asn Gly Tyr Thr Tyr Glu Asp Tyr Gln
1 5 10 15
Asp Thr Ala Lys Trp Leu Leu Ser His Thr Glu Gln Arg Pro Gln Val
20 25 30
Ala Val Ile Cys Gly Ser Gly Leu Gly Gly Leu Val Asn Lys Leu Thr
35 40 45
Gln Ala Gln Thr Phe Asp Tyr Ser Glu Ile Pro Asn Phe Pro Glu Ser
50 55 60
Thr Val Pro Gly His Ala Gly Arg Leu Val Phe Gly Ile Leu Asn Gly
65 70 75 80
Arg Ala Cys Val Met Met Gln Gly Arg Phe His Met Tyr Glu Gly Tyr
85 90 95
Pro Phe Trp Lys Val Thr Phe Pro Val Arg Val Phe Arg Leu Leu Gly
100 105 110
Val Glu Thr Leu Val Val Thr Asn Ala Ala Gly Gly Leu Asn Pro Asn
115 120 125
Phe Glu Val Gly Asp Ile Met Leu Ile Arg Asp His Ile Asn Leu Pro
130 135 140
Gly Phe Ser Gly Glu Asn Pro Leu Arg Gly Pro Asn Glu Glu Arg Phe
145 150155 160
Gly Val Arg Phe Pro Ala Met Ser Asp Ala Tyr Asp Arg Asp Met Arg
165 170 175
Gln Lys Ala His Ser Thr Trp Lys Gln Met Gly Glu Gln Arg Glu Leu
180 185 190
Gln Glu Gly Thr Tyr Val Met Leu Gly Gly Pro Asn Phe Glu Thr Val
195 200 205
Ala Glu Cys Arg Leu Leu Arg Asn Leu Gly Ala Asp Ala Val Gly Met
210 215 220
Ser Thr Val Pro Glu Val Ile Val Ala Arg His Cys Gly Leu Arg Val
225 230 235 240
Phe Gly Phe Ser Leu Ile Thr Asn Lys Val Ile Met Asp Tyr Glu Ser
245 250 255
Gln Gly Lys Ala Asn His Glu Glu Val Leu Glu Ala Gly Lys Gln Ala
260 265 270
Ala Gln Lys Leu Glu Gln Phe Val Ser Leu Leu Met Ala Ser Ile Pro
275 280 285
Val Ser Gly His Thr Gly
290
<210>6
<211>299
<212>PRT
<213> Artificial Sequence (Artificial Sequence)
<400>6
His His His His His His Lys Leu Asp Val Ile Gly Ile Gly Asn Leu
1 5 10 15
Asn Tyr Asp Ile Ile Phe Thr Leu Glu Arg Phe Pro Glu Phe His Glu
20 25 30
Lys Ile Asn Ala Arg Gly Ala His Phe Gly Leu Gly Gly Ala Ala Ala
35 40 45
Asn Thr Ile Ser Trp Leu Ala His Phe Gly Leu Lys Thr Gly Tyr Ile
50 55 60
Gly Ala Val Gly Asn Asp Asp Val Gly Glu Met His Ile Lys Tyr Phe
65 70 75 80
Gln Gly Ile Gly Val Asp Thr Gly Gly Ile Asp Val Val Glu Glu Pro
85 90 95
Ser Gly Val Ala Val Ala Met Val Ala Gly Asp Asp Lys Arg Ile Val
100 105 110
Lys Tyr Pro Gly Ala Asn Leu Arg Arg Arg Phe Lys Pro Glu Tyr Ala
115 120 125
Ser Arg Ala Lys Phe Leu His Leu Ser Ser Asn Pro Pro Glu Leu Ile
130 135 140
Glu Glu Ala Val Asn Phe Ala Ser Gln Arg Gly Ile Lys Val Ser Leu
145 150155 160
Asp Ile Gly Glu Ala Pro Leu Pro Arg Glu Leu Glu Ser Lys Val Asp
165 170 175
Tyr Leu Met Met Asn Glu Asp Glu Tyr Arg Arg Lys Tyr Gly Ser Leu
180 185 190
Asp Pro Ser Leu Cys Arg Ala Lys Asn Leu Val Val Thr Leu Asn Gly
195 200 205
Gly Gly Ala Leu Val Arg Glu Gly Asp Asn Val Phe Glu Val Arg Gly
210 215 220
Leu Ser Ala Lys Val Val Asp Ser Thr Gly Ala Gly Asp Ser Phe Asp
225 230 235 240
Ala Gly Val Ile Tyr Gly Val Leu Asn Gly Trp Ser Leu Leu Asp Ser
245 250 255
Ala Lys Leu Gly Met Leu Leu Ala Tyr Leu Thr Val Gln Lys Val Gly
260 265 270
Ala Arg Ser Ala Ile Val Pro Leu Glu Glu Val Lys Arg Ile Ala Arg
275 280 285
Glu Val Gly Leu Asp Leu Pro Phe Asn Arg Thr
290 295
<210>7
<211>190
<212>PRT
<213> Artificial Sequence (Artificial Sequence)
<400>7
Met Gly Lys Leu Ile Trp Leu Met Gly Pro Ser Gly Ser Gly Lys Asp
1 5 10 15
Ser Leu Leu Ala Glu Leu Arg Leu Arg Glu Gln Thr Gln Leu Leu Val
20 25 30
Ala His Arg Tyr Ile Thr Arg Asp Ala Ser Ala Gly Ser Glu Asn His
35 40 45
Ile Ala Leu Ser Glu Gln Glu Phe Phe Thr Arg Ala Gly Gln Asn Leu
50 55 60
Leu Ala Leu Ser Trp His Ala Asn Gly Leu Tyr Tyr Gly Val Gly Val
65 70 75 80
Glu Ile Asp Leu Trp Leu His Ala Gly Phe Asp Val Leu Val Asn Gly
85 90 95
Ser Arg Ala His Leu Pro Gln Ala Arg Ala Arg Tyr Gln Ser Ala Leu
100 105 110
Leu Pro Val Cys Leu Gln Val Ser Pro Glu Ile Leu Arg Gln Arg Leu
115 120 125
Glu Asn Arg Gly Arg Glu Asn Ala Ser Glu Ile Asn Ala Arg Leu Ala
130 135 140
Arg Ala Ala Arg Tyr Thr Pro Gln Asp Cys His Thr Leu Asn Asn Asp
145 150 155 160
Gly Ser Leu Arg Gln Ser Val Asp Thr Leu Leu Thr Leu Ile His Gln
165 170 175
Lys Glu Lys His His Ala Cys Leu His His His His His His
180 185 190
<210>8
<211>543
<212>PRT
<213> Artificial Sequence (Artificial Sequence)
<400>8
Ala Ala Glu Gln Asp Pro Glu Ala Arg Ala Ala Ala Arg Pro Leu Leu
1 5 10 15
Thr Asp Leu Tyr Gln Ala Thr Met Ala Leu Gly Tyr Trp Arg Ala Gly
20 25 30
Arg Ala Arg Asp Ala Ala Glu Phe Glu Leu Phe Phe Arg Arg Cys Pro
35 40 45
Phe Gly Gly Ala Phe Ala Leu Ala Ala Gly Leu Arg Asp Cys Val Arg
50 55 60
Phe Leu Arg Ala Phe Arg Leu Arg Asp Ala Asp Val Gln Phe Leu Ala
65 70 75 80
Ser Val Leu Pro Pro Asp Thr Asp Pro Ala Phe Phe Glu His Leu Arg
85 90 95
Ala Leu Asp Cys Ser Glu Val Thr Val Arg Ala Leu Pro Glu Gly Ser
100 105 110
Leu Ala Phe Pro Gly Val Pro Leu Leu Gln Val Ser Gly Pro Leu Leu
115 120 125
Val Val Gln Leu Leu Glu Thr Pro Leu Leu Cys Leu Val Ser Tyr Ala
130 135 140
Ser Leu Val Ala Thr Asn Ala Ala Arg Leu Arg Leu Ile Ala Gly Pro
145 150 155 160
Glu Lys Arg Leu Leu Glu Met Gly Leu Arg Arg Ala Gln Gly Pro Asp
165 170 175
Gly Gly Leu Thr Ala Ser Thr Tyr Ser Tyr Leu Gly Gly Phe Asp Ser
180 185 190
Ser Ser Asn Val Leu Ala Gly Gln Leu Arg Gly Val Pro Val Ala Gly
195 200 205
Thr Leu Ala His Ser Phe Val Thr Ser Phe Ser Gly Ser Glu Val Pro
210 215 220
Pro Asp Pro Met Leu Ala Pro Ala Ala Gly Glu Gly Pro Gly Val Asp
225 230 235 240
Leu Ala Ala Lys Ala Gln Val Trp Leu Glu Gln Val Cys Ala His Leu
245 250 255
Gly Leu Gly Val Gln Glu Pro His Pro Gly Glu Arg Ala Ala Phe Val
260 265 270
Ala Tyr Ala Leu Ala Phe Pro Arg Ala Phe Gln Gly Leu Leu Asp Thr
275 280 285
Tyr Ser Val Trp Arg Ser Gly Leu Pro Asn Phe Leu Ala Val Ala Leu
290 295 300
Ala Leu Gly Glu Leu Gly Tyr Arg Ala Val Gly Val Arg Leu Asp Ser
305 310 315 320
Gly Asp Leu Leu Gln Gln Ala Gln Glu Ile Arg Lys Val Phe Arg Ala
325 330 335
Ala Ala Ala Gln Phe Gln Val Pro Trp Leu Glu Ser Val Leu Ile Val
340 345 350
Val Ser Asn Asn Ile Asp Glu Glu Ala Leu Ala Arg Leu Ala Gln Glu
355 360 365
Gly Ser Glu Val Asn Val Ile Gly Ile Gly Thr Ser Val Val Thr Cys
370 375 380
Pro Gln Gln Pro Ser Leu Gly Gly Val Tyr Lys Leu Val Ala Val Gly
385 390 395 400
Gly Gln Pro Arg Met Lys Leu Thr Glu Asp Pro Glu Lys Gln Thr Leu
405 410 415
Pro Gly Ser Lys Ala Ala Phe Arg Leu Leu Gly Ser Asp Gly Ser Pro
420 425 430
Leu Met Asp Met Leu Gln Leu Ala Glu Glu Pro Val Pro Gln Ala Gly
435 440 445
Gln Glu Leu Arg Val Trp Pro Pro Gly Ala Gln Glu Pro Cys Thr Val
450 455 460
Arg Pro Ala Gln Val Glu Pro Leu Leu Arg Leu Cys Leu Gln Gln Gly
465 470 475 480
Gln Leu Cys Glu Pro Leu Pro Ser Leu Ala Glu Ser Arg Ala Leu Ala
485 490 495
Gln Leu Ser Leu Ser Arg Leu Ser Pro Glu His Arg Arg Leu Arg Ser
500 505 510
Pro Ala Gln Tyr Gln Val Val Leu Ser Glu Arg Leu Gln Ala Leu Val
515 520 525
Asn Ser Leu Cys Ala Gly Gln Ser Pro His His His His His His
530 535 540
Claims (10)
1. A health-care product for pet is prepared from β -1, 3-glucan 0.01-50 wt% and nicotinamide mononucleotide 0.01-50 wt%.
2. The pet health product of claim 1, wherein the mass ratio of β -1,3 glucan to nicotinamide mononucleotide is 1 (1-100).
3. The pet health product of claim 1, wherein said nicotinamide mononucleotide is more than 99% pure and said β -1,3 glucan is more than 70% pure.
4. The pet food of claim 1, further comprising an additional active ingredient comprising at least one of a vitamin, an antioxidant, and a mineral.
5. The pet health product of claim 4, wherein the vitamins include one or more of vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin D, and vitamin E; the antioxidant comprises one or more of butylated hydroxyanisole, dibutyl hydroxy toluene, propyl gallate, D-sodium erythorbate and tea polyphenol; the mineral comprises mineral elements including one or more of magnesium, iron, zinc, copper, calcium, iodine and manganese.
6. The pet food of claim 1, further comprising one or more of a filler, an excipient, and a preservative.
7. The pet health product of claim 1, wherein the daily amount of β -1,3 glucan in the pet health product is 1-1000 micrograms/kg body weight and the nicotinamide mononucleotide is 1-2000 micrograms/kg body weight.
8. A method of preparing a pet health product according to any one of claims 1 to 7, comprising:
weighing the components according to the formula proportion, putting the components into a stirring pot, and stirring to obtain a mixed material; and then, after forming and drying, cooling to room temperature, and then accommodating in a packaging container and sealing to obtain the pet health product.
9. The method of claim 8, wherein said β -1,3 glucan is produced by a fermentation process comprising:
preparing a culture solution, inoculating zymophyte into the culture solution, fermenting at 28-32 ℃ until the OD600 value of the culture solution is more than 0.6-0.9, and then separating and extracting β -1,3 glucan, wherein the culture solution contains potassium dihydrogen phosphate, sodium nitrate, magnesium sulfate, calcium chloride, ferrous chloride, sucrose and agar.
10. The method of claim 8, wherein the method of synthesizing nicotinamide mononucleotide comprises:
constructing a biological enzyme recombinant plasmid, and performing protein expression and purification to obtain biological enzymes, wherein the biological enzymes comprise a first biological enzyme, a second biological enzyme, a third biological enzyme and a fourth biological enzyme; the first biological enzyme comprises the amino acid sequence as set forth in SEQ ID NO:1 and the second biological enzyme comprises the nucleotide sequence shown as SEQ ID NO: 2, and the third biological enzyme comprises the nucleotide sequence shown as SEQ ID NO: 3 and the fourth biological enzyme comprises the nucleotide sequence shown as SEQ ID NO: 4;
preparing a reaction solution, wherein the reaction solution contains inosine, adenosine diphosphate and adenosine triphosphate, adding the first biological enzyme, the second biological enzyme and the third biological enzyme into the reaction solution, generating 5-phosphoribosyl pyrophosphate after biocatalysis, adding nicotinamide and the fourth biological enzyme, and separating to obtain nicotinamide mononucleotide after biocatalysis.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010133729.1A CN111184133B (en) | 2020-02-28 | 2020-02-28 | Health-care product for pets and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010133729.1A CN111184133B (en) | 2020-02-28 | 2020-02-28 | Health-care product for pets and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111184133A true CN111184133A (en) | 2020-05-22 |
CN111184133B CN111184133B (en) | 2023-05-26 |
Family
ID=70702847
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010133729.1A Active CN111184133B (en) | 2020-02-28 | 2020-02-28 | Health-care product for pets and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111184133B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111643394A (en) * | 2020-06-29 | 2020-09-11 | 上海圣岳生物科技有限公司 | Cosmetic emulsion containing beta-nicotinamide mononucleotide and preparation method thereof |
CN113016957A (en) * | 2021-04-30 | 2021-06-25 | 云南爱尔康生物技术有限公司 | Pet food additive containing astaxanthin and NMN and preparation method thereof |
CN115530289A (en) * | 2022-09-27 | 2022-12-30 | 深圳壹零捌生物工程科技有限公司 | Compound life cell nutrient for pets |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104349784A (en) * | 2012-02-22 | 2015-02-11 | 艾尔格科技公司 | Animal feed compositions and methods of using the same |
CN108026517A (en) * | 2016-07-30 | 2018-05-11 | 邦泰生物工程(深圳)有限公司 | A kind of Nampt mutant and its application |
CN110338268A (en) * | 2019-08-19 | 2019-10-18 | 上海昱仪网络科技有限公司 | It is a kind of to provide the Compound Supplement of comprehensive health-care function for pet grain |
-
2020
- 2020-02-28 CN CN202010133729.1A patent/CN111184133B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104349784A (en) * | 2012-02-22 | 2015-02-11 | 艾尔格科技公司 | Animal feed compositions and methods of using the same |
CN108026517A (en) * | 2016-07-30 | 2018-05-11 | 邦泰生物工程(深圳)有限公司 | A kind of Nampt mutant and its application |
CN110338268A (en) * | 2019-08-19 | 2019-10-18 | 上海昱仪网络科技有限公司 | It is a kind of to provide the Compound Supplement of comprehensive health-care function for pet grain |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111643394A (en) * | 2020-06-29 | 2020-09-11 | 上海圣岳生物科技有限公司 | Cosmetic emulsion containing beta-nicotinamide mononucleotide and preparation method thereof |
CN113016957A (en) * | 2021-04-30 | 2021-06-25 | 云南爱尔康生物技术有限公司 | Pet food additive containing astaxanthin and NMN and preparation method thereof |
CN115530289A (en) * | 2022-09-27 | 2022-12-30 | 深圳壹零捌生物工程科技有限公司 | Compound life cell nutrient for pets |
Also Published As
Publication number | Publication date |
---|---|
CN111184133B (en) | 2023-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111184133B (en) | Health-care product for pets and preparation method thereof | |
US6984507B2 (en) | Biological compositions and methods for treatment of lung cancer | |
EP3319620B1 (en) | Lactobacillus paracasei for the production of conjugated linoleic acid, nutritional and pharmaceutical preparations containing it and uses thereof | |
KR20110070977A (en) | Method for producing biological heme iron, and iron supplementing composition containing the heme iron produced by same | |
KR101488481B1 (en) | Glycoside hydrolase From lactic acid bacteria And Use Thereof | |
CN110195036A (en) | A kind of recombination Corynebacterium glutamicum of high yield acetylglucosamine and its application | |
CN102286601A (en) | Method for preparing peanut antioxidant peptide by fermentation | |
CN108085265B (en) | Bacillus coagulans new strain, and microecological preparation and feed thereof | |
JP6975239B2 (en) | Psicose Epimerization Enzyme-producing Psicose production method using microorganisms | |
CN114836342B (en) | Lactic acid bacteria GS-3 and application thereof in selenium enrichment | |
KR20160083329A (en) | Composition comprising neoagarooligosaccharide for preventing or treating sepsis or septic shock | |
TW201928062A (en) | Method for producing butyric acid and/or its salts | |
KR101514775B1 (en) | Glycoside hydrolase From lactic acid bacteria And Use Thereof | |
CN108192899B (en) | Streptococcus zooepidemicus lactate dehydrogenase gene mutant and application thereof | |
CN1306025C (en) | Culture medium its rpeparation method and method for culturing lact-streptocin | |
Wang et al. | Efficient preparation of selenium/glutathione-enriched Candida utilis and its biological effects on rats | |
CN117343976A (en) | Method for coproducing glyceroglycosides and D-psicose by double enzyme cascading | |
CN116058432A (en) | Citric acid mycelium residue microbial feed additive and preparation method and application thereof | |
WO2019127829A1 (en) | Fermentation production method for oxidized coenzyme q10, and high-content oxidized coenzyme q10 prepared therefrom | |
Wang et al. | Direct isomaltulose synthesis from beet molasses by immobilized sucrose isomerase | |
KR101743421B1 (en) | Anticariogenic use of 3,6-anhydro-L-galactose | |
JP2011036203A (en) | Probiotics proliferation promoter | |
JPH0638745A (en) | Neutral phytase and its production | |
CN101711775B (en) | Fermentation composition for fermenting Agaricus blazei Murrill through probiotics | |
CN105861411A (en) | Method for improving clostridium butyricum fermentation growth efficiency |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |